Incyte Reports Third Quarter 2026 Financial Results and Provides Business Updates
Business Wire•29/10/2026•07:00 ET
0
Key Highlights
- ➤Total revenue $1.56 billion, up 14% year over year
- ➤Opzelura net sales $255 million, up 36% year over year
- ➤2026 total net sales guidance raised to $5.21-$5.30 billion
- ➤Vega acquisition adds latarcibart for $1.25 billion, plus $750 million milestones
- ➤GAAP R&D expense rose 254% to $1.79 billion, including $1.23 billion Vega charge
Expert Statements
Bill Meury, Chief Executive Officer, Incyte
“Our third quarter was marked by strong commercial performance, meaningful pipeline progress and important regulatory achievements.”
Bill Meury, Chief Executive Officer, Incyte
“Net sales growth was strong in both the U.S. and internationally, creating a durable core business beyond Jakafi.”
Bill Meury, Chief Executive Officer, Incyte
“At the same time, we are advancing a pipeline led by a CALR-targeted monoclonal antibody for myeloproliferative neoplasms, a novel Protein S modulator for von Willebrand disease, a KRAS G12D inhibitor for pancreatic and colorectal cancers and a TGFβR2×PD-1 bispecific antibody for colorectal cancer.”
Bill Meury, Chief Executive Officer, Incyte
“Each represents a significant opportunity for Incyte, and together they give us multiple paths to growth beyond 2029.”
Bill Meury, Chief Executive Officer, Incyte
“With important clinical, regulatory and commercial catalysts ahead, we are well positioned to create long-term value for patients and shareholders.”
Incyte Reports Third Quarter 2026 Financial Results and Provides Business Updates
Total revenue of $1.56 billion and total net sales of $1.32 billion in the third quarter of 2026, each an increase of 14% compared to the third quarter of 2025
Get started
Create a free account to read the full story.